Although Novum is growing, we maintain an adherence to small-company values. Access to senior management throughout the project cycle, a high degree of interaction with client services, and transparency in pricing and timelines are just some of the ways that we build partnerships with our clients.

Here is the team that makes sure every study is a true partnership:

Mr. Chamberlain joined Novum in 2012 to lead the company’s strategic direction, operations and business management. Prior to joining Novum, Mr. Chamberlain was an executive in the media industry, most recently president of Pittsburgh’s leading media company, the Pittsburgh Post-Gazette. Previously, Mr. Chamberlain worked in executive, operational, strategic planning and business development roles at The New York Times and the Journal Register Company. Earlier in his career, Mr. Chamberlain was in the economic development field at a nongovernmental organization in Washington, D.C., where he conducted international development policy and program work.

Mr. Chamberlain holds an MBA from New York University and a BA in English literature from Colby College in Maine.

Dr. Gallicano brings more than 23 years of pharmaceutical experience to Novum. He has a background in pharmacokinetics, biopharmaceutics, biostatistics, bioanalytics and clinical trial design. He has previously served as scientific director for CroMedica Prime/Prime Trials, vice president of Research and Development and director of Pharmacokinetics for Axelson Biopharma Research, and director of Biopharmaceutics for Watson Laboratories. In his current position, he is responsible for leading a team of scientists and statisticians in developing protocols, analyzing data and generating high-quality final study reports for clinical research studies performed by Novum.

Dr. Gallicano earned a PhD in chemistry from the University of British Columbia.

Ms. Gongas has 18 years of experience within the science and clinical medicine fields; 15 years of that experience is with Novum. She has held a wide range of positions with increasing responsibility. In a career spanning cost analysis, project management and study conduct, Ms. Gongas currently has a senior leadership role with Novum. Her understanding of the complexity of clinical research has helped her to direct the management and daily operations of all clinical endpoint studies. Ms. Gongas helped to establish the one-of-a-kind Novum Clinical Research Associate Academy. In this innovative program, clinical research associates receive structured, comprehensive training in all aspects of clinical research.

Ms. Gongas is a member of the Society of Clinical Research Professionals and the Society of Clinical Research Associates.

Dr. Brimhall has worked with Novum since the opening of our Las Vegas clinic in 2004. He joined the company full-time in January 2009 and now heads all Early Phase operations at Novum. Dr. Brimhall has been intimately involved with study feasibility, protocol authoring and review, study planning and logistics, pharmacovigilance, and ensuring the safety and well-being of our study participants. He has served as the Principal Investigator on more than 500 studies (Phase I-IV) with a primary emphasis on bioavailability and bioequivalence.

Dr. Brimhall has a BS in mathematics from Brigham Young University and a DO from Des Moines University-Osteopathic Medical Center. He completed postgraduate training at Forest Park Hospital, an affiliate of the St. Louis University Hospital System with an ACGME-accredited internal medicine program, where he was the chief resident.

Dr. Brimhall is a Diplomat of the American Board of Internal Medicine, a Fellow of the American College of Physicians, a Certified Physician Investigator from the Academy of Physicians in Clinical Research, and a member of the Association of Clinical Research Professionals.

Dr. Copa joined Novum in 2013 to oversee clinical expansion efforts. He has more than 20 years of experience in contract research organizations, serving in a variety of roles ranging from director of Clinical Research to site president, and most recently chief scientific officer of a 554-bed clinical pharmacology unit (CPU). The CPU specialized in FIH studies, cardiac safety studies, bioequivalence studies and topical product studies.

Dr. Copa received his Doctor of Pharmacy degree from the University of Minnesota College of Pharmacy. He then completed a two-year fellowship in cardiovascular research and critical care medicine through the University of Minnesota.

Ms. Lavrich began her career at the University of Pittsburgh Medical Center. She has been with Novum for more than 16 years in Clinical Operations and has held a wide range of positions with increasing responsibility. Ms. Lavrich has been instrumental in the growth and development of Novum. She oversees all study support units and ensures consistency of standards throughout our organization. Ms. Lavrich has been involved in more than 20 Early Phase FDA audits during her tenure at Novum.

She is currently pursuing an MS in health sciences, focusing on regulatory affairs, at George Washington University. She previously earned a BS in health sciences, focusing on clinical research administration, from George Washington University. She is also a Certified Clinical Research Coordinator from the Association of Clinical Research Professionals (ACRP).